Shen Qin, Wu Jim Zhen, Wong Jason C
Roche R&D Center (China), Building 5, No.720 Cai Lun Road, Shanghai 201203, China.
Drug Discov Today. 2013 Dec;18(23-24):1334-41. doi: 10.1016/j.drudis.2013.08.018. Epub 2013 Sep 5.
Diabetic retinopathy (DR) is of great interest to the drug discovery community owing to the rising worldwide prevalence of diabetes and its associated complications. The complex molecular mechanism associated with DR development and the poor translatability of available animal models to late-stage DR are considered to be major hurdles for drug discovery. Here we will provide an overview of the mechanistic rationale as well as clinical efficacy of drug candidates, and highlight emerging and potential targets for therapeutic intervention at different stages of DR.
由于全球糖尿病患病率及其相关并发症不断上升，糖尿病视网膜病变（DR）引起了药物研发界的极大兴趣。与DR发展相关的复杂分子机制以及现有动物模型对晚期DR的低可转化性被认为是药物研发的主要障碍。在此，我们将概述候选药物的作用机制原理以及临床疗效，并强调在DR不同阶段进行治疗干预的新兴和潜在靶点。
